Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

To evaluate the objective response rate, disease control rate, progression-free survival, overall survival, surgical conversion rate and safety of irinotecan liposome combined with 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer patients.

Trial Details

NCT ID

NCT06341296

Phase

PHASE2

Sponsor

West China Hospital

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

Irinotecan Liposome
5-FU
LV
Bevacizumab

Locations (sample)

Sichuan, Sichuan, Chengdu, China|35.1221,105.48032

Key Eligibility Criteria

18\~85 years old.
Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma.
RAS/BRAF v600e mutant or right half colon cancer is known.
pMMR/MSS is known.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →